CD8A and neoplasm: Consequently, BT_CD103N_T cells from tumor tissue in both datasets displayed higher anti-tumor effector signature scores compared to their circulating counterparts (BT_CD103N_B) and bulk peripheral CD8+ T cells (Fig. 7d).